Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2026 According to a Neurocrine Biosciences media release, data from the trial were presented at ENDO 2026.
24 Apr 2026 According to a European Medicines Agency media release, An application for an initial marketing authorisation was withdrawn. Viokat (diazoxide choline) was developed for the treatment of hyperphagia, extreme hunger that cannot be satisfied, in people with Prader-Willi syndrome, a genetic condition that affects growth, development and behaviour.
05 Jan 2026 According to a Soleno Therapeutics media release, data from this trial was published in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com